Eisai (ESALY) Stock Price, News & Analysis

Company Overview

Eisai Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines and healthcare products. The company focuses primarily on neuroscience and oncology, with additional products in areas such as neurology, gastrointestinal disorders and preventive healthcare.

Eisai’s marketed medicines include Leqembi (lecanemab), an Alzheimer’s disease treatment developed in collaboration with Biogen; Dayvigo for insomnia; Fycompa for epilepsy; and Halaven for certain cancers. Eisai also co-develops and commercializes Lenvima, an oncology medicine, with Merck & Co. The company’s healthcare portfolio includes over-the-counter products and other consumer health offerings in selected markets.

Founded in Japan in 1941, Eisai has expanded its operations internationally and serves patients and healthcare professionals across Japan, the United States, Europe and other markets in Asia and around the world. Its research activities are concentrated on areas with significant unmet medical needs, including dementia, neurological diseases and cancer.

Key Stats

• Today's Range: $61.00 to $63.29
• 50-Day Range: $61.51 to $61.51
• 52-Week Range: $36.88 to $73.90
• Volume: 331,800 shs
• Average Volume: 60,916 shs
• Market Capitalization: $17.64 billion
• P/E Ratio: 70.70
• Dividend Yield: 1.43%
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/04/2021
• Today: 9/13/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ESALY
• CIK: 948406
• Web: www.eisai.co.jp
• Phone: (133) 817-3700
• Fax: 813-3811-6032
• Employees: 11,322
• Year Founded: 1941

Profitability

• EPS (Trailing Twelve Months): $0.87
• Trailing P/E Ratio: 70.70
• Forward P/E Ratio: 32.37
• P/E Growth: 2.46
• Net Income: $426.79 million
• Net Margins: 4.11%
• Pretax Margin: N/A
• Return on Equity: 3.86%
• Return on Assets: 2.50%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 2.20
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: $6.74 billion
• Price / Sales: 2.62
• Cash Flow: $2.68 per share
• Price / Cash Flow: 22.94
• Book Value: $23.94 per share
• Price / Book: 2.57

Miscellaneous

• Outstanding Shares: 286,770,000
• Free Float: N/A
• Market Cap: $17.64 billion
• Optionable: Not Optionable
• Beta: 0.31